A key concern in pharmaceutical R&D is developing and using the best decision tools (e.g. models, assays) to advance disease knowledge and accurately assess therapeutic candidates. In the latest Perspectives review published recently …Read more
How can the use of human stem cell models of neurodegenerative disease advance drug discovery?
In this article hosted by Oxford Global, Dr. Clare Jones, Chief Scientific Officer at Talisman Therapeutics, outlines the …Read more
Human stem cell models offer invaluable insights into how neurodegenerative diseases such as Alzheimer’s and Parkinson’s affect the brain. In this article hosted by Oxford Global, Dr. Clare Jones, Chief Scientific Officer at …Read more
Talisman Therapeutics is delighted to be one of 10 biotech and life sciences companies from the UK to have been selected to participate at the Fast-Track Programme to Barcelona-Catalonia Life Science Hub, Catalonia …Read more
Dr. Clare Jones, Talisman’s CSO, will be speaking at the Biomarkers UK conference in Manchester next week (8-9th November 2021), introducing Talisman’s neurodegenerative disease modelling platforms and showcasing some recent work.
Biomarkers UK …Read more
Talisman CSO, Dr. Clare Jones, will be speaking at the Cambridge New Therapeutics Forum tonight, giving a talk titled: “Use of human stem cell models of neurodegeneration to advance drug discovery”.
Do come …Read more
Talisman CSO, Dr. Clare Jones, will be speaking at the Cell UK conference in London next week (28 – 29 October 2021), giving a talk titled: “Use of human stem cell models of …Read more
Talisman Therapeutics CSO, Dr. Clare Jones, will be presenting a key note talk titled “The use of human stem cell models of neurodegenerative disease to advance drug discovery” at the Precision in Drug …Read more
We are delighted to announce that Dr Clare Jones was promoted to Chief Scientific Officer on 1st July 2021. Previously, she held the role of Head of R&D at the company for four …Read more
PUBLICATION: Cell Reports, Volume 22, Issue 13, 27 March 2018, Pages 3612-3624
Lewis D. Evans 4, Thomas Wassmer 4, Graham Fraser, James Smith, Michael Perkinton, Andrew Billinton,
Frederick J. Livesey 5…